Get to know our clinical trials
Clinical trial to test how much CagriSema (1.0 mg/week) reduces blood glucose and body weight compared to tirzepatide (5 mg/week) in people with type 2 diabetes receiving treatment with metformin, an SGLT2 inhibitor, or both.
THIS STUDY WILL PRIMARILY INVESTIGATE CHANGES IN BLOOD GLUCOSE LEVELS AND BODY WEIGHT. THE CHANGES OBSERVED IN PEOPLE TAKING CAGRISEMA WILL BE COMPARED WITH CHANGES IN PEOPLE TAKING TIRZEPATIDE.
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- RESEARCH STUDY TO TEST HOW MUCH CAGRISEMA (1.0 MG ONCE A WEEK) REDUCES BLOOD GLUCOSE AND BODY WEIGHT COMPARED TO TIRZEPATIDE (5 MG ONCE A WEEK) IN PEOPLE WITH TYPE 2 DIABETES RECEIVING TREATMENT WITH METFORMIN, AN SGLT2 INHIBITOR, OR BOTH
- Code EudraCT: 2023-509600-15
- Protocol number: NN9388-7741
- Promoter: Novo Nordisk Pharma
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.